Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart drug showdown: which Beta-Blocker best protects ICD patients?

NCT ID NCT06964464

Disease control Sponsor: University of Rochester Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares two common heart failure medications, carvedilol and metoprolol succinate, in 2,000 adults who have an implantable cardioverter defibrillator (ICD). Participants currently taking metoprolol will be randomly assigned to either stay on it or switch to carvedilol. Researchers will track which group has fewer heart-related hospitalizations, ICD shocks, or deaths over up to 3 years. The goal is to find out if one drug works better for this specific group of patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
carvedilol and metoprolol succinate (beta-blocker drugs)
What this could lead to
If it works, this could show which beta-blocker is better at preventing heart-related hospitalizations, ICD shocks, or death in heart failure patients with an ICD.
What could go wrong
This is a Phase 4 trial, so both drugs are already approved, but the study is open-label (not blinded), which may introduce bias. Results may not apply to all heart failure patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jul 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * ICD implanted for primary prevention for HFrEF (either ICM or NICM) with remote monitoring capability * Current treatment with metoprolol succinate and willing to switch to carvedilol * LVEF \<50% during the past 12 months prior to consent Exclusion Criteria: * Unwilling or unable to follow the protocol * Treatment with any other ßB than metoprolol succinate or no ßB treatment * Known prior intolerance or contraindication to carvedilol * Systolic blood pressure \<100 mmHg * Enrollment in another clinical trial * Inability or unwilling to consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Beta-blocker therapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac cardiomyopathy Death, Sudden, Cardiac heart failure sudden arrhythmia death syndrome sudden cardiac arrest systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Beta-blocker therapy Cardiomyopathy Heart failure with reduced ejection fraction (hfref) Implantable cardioverter defibrillator (ICD) Sudden cardiac death Ventricular arrhythmia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    13 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AdventHealth Redmond

    RECRUITING

    Rome, Georgia, 30165, United States

  • AdventHealth Shawnee Mission

    RECRUITING

    Shawnee Mission, Kansas, 66204, United States

  • CHRISTUS Trinity Mother Frances Health System

    RECRUITING

    Tyler, Texas, 75701, United States

  • Creighton University Medical Center

    RECRUITING

    Omaha, Nebraska, 68124, United States

  • Health University of Utah

    RECRUITING

    Salt Lake City, Utah, 84112, United States

  • Henry Ford Health System

    RECRUITING

    Detroit, Michigan, 48202, United States

  • HonorHealth

    RECRUITING

    Scottsdale, Arizona, 85258, United States

  • New York-Presbyterian Brooklyn Methodist Hospital

    RECRUITING

    Brooklyn, New York, 11215, United States

  • Suny Downstate

    RECRUITING

    Brooklyn, New York, 11203, United States

  • University of Mossouri

    RECRUITING

    Columbia, Missouri, 65212, United States

  • University of Rochester Medical Center

    RECRUITING

    Rochester, New York, 14642, United States

  • University of Wisconsin Hospital and Clinics

    RECRUITING

    Madison, Wisconsin, 53792, United States

  • Virginia Commonwealth University

    RECRUITING

    Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.